Allogene Therapeutics (ALLO) Enterprise Value (2019 - 2025)
Allogene Therapeutics (ALLO) has disclosed Enterprise Value for 7 consecutive years, with -$250.2 million as the latest value for Q4 2025.
- Quarterly Enterprise Value rose 14.45% to -$250.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$250.2 million through Dec 2025, up 14.45% year-over-year, with the annual reading at -$250.2 million for FY2025, 14.45% up from the prior year.
- Enterprise Value hit -$250.2 million in Q4 2025 for Allogene Therapeutics, up from -$252.2 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$250.2 million in Q4 2025 to a low of -$699.6 million in Q1 2021.
- Historically, Enterprise Value has averaged -$417.3 million across 5 years, with a median of -$439.8 million in 2023.
- Biggest YoY gain for Enterprise Value was 51.7% in 2021; the steepest drop was 46.0% in 2021.
- Year by year, Enterprise Value stood at -$399.9 million in 2021, then dropped by 16.84% to -$467.2 million in 2022, then increased by 4.94% to -$444.1 million in 2023, then skyrocketed by 34.14% to -$292.5 million in 2024, then rose by 14.45% to -$250.2 million in 2025.
- Business Quant data shows Enterprise Value for ALLO at -$250.2 million in Q4 2025, -$252.2 million in Q3 2025, and -$273.1 million in Q2 2025.